Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo

Learn

What is Cannabinol (CBN)?

Cannabinol (CBN) is a rare cannabinoid showing unique, potentially medically important properties for diseases with high unmet medical needs. Cannabinol is one of the more than 100 cannabinoid compounds present in the Cannabis plant, albeit at very low levels, which classifies it as a rare or minor cannabinoid. Is cannabinol safe? Is cannabinol psychoactive?

learn More about cannabinol

What is Epidermolysis Bullosa (EB)?

Epidermolysis bullosa, or EB, is a group of rare genetic skin diseases characterized by fragile skin that can lead to extensive blistering and wounding. It affects skin and mucous membranes, particularly of the gastrointestinal tract, genitourinary and respiratory systems. It is a debilitating disease affecting a small number of people, thus earning it an orphan-disease status. The disease has no definitive cure and all current treatments are directed towards symptom relief.

Learn More About Epidermolysis Bullosa

What is Glaucoma?

Glaucoma is a group of eye diseases which results in damage to the optic nerve due to high intraocular pressure (IOP) of the eye from fluid build-up. Glaucoma is the second leading cause of vision loss.

Learn More About Glaucoma

GMP Manufacturing Standards by Product Type

What are the GMP requirements for pharmaceuticals, medicinal cannabis, cosmetics, dietary supplements, and food and beverage products?

Good Manufacturing Practices, or GMP for short, are minimum manufacturing standards required for different industries. Learn about how GMP requirements differ based on product type.

Learn about GMP Manufacturing Standards

Cannabis Treatments for Glaucoma

The use of cannabis to treat glaucoma has extensive anecdotal evidence and supporting clinical data in the literature. It has been definitively demonstrated in articles that smoking cannabis lowers intraocular pressure (IOP) in both normal individuals and in those with glaucoma. Although the role of cannabinoids in treating glaucoma is thought to be very well understood according to the 2004 publication from Tomida, et al., entitled “Cannabinoids and glaucoma”, no such products are currently approved for this disease.

Learn about Cannabis Treatments for Glaucoma

Cannabinoid Science

Cannabinoids fall into three general types: (1) phytocannabinoids, such as those that can be isolated from the Cannabis plant; (2) endogenous cannabinoids (“endocannabinoids”), which are produced naturally in the bodies of humans and animals; and (3) synthetic cannabinoids, which are produced in the laboratory and may have structural deviations from the naturally occurring drugs.

Learn about Cannabinoid Science

Articles and Videos

Find articles, posters and videos about various topics such as cannabinol (CBN), biosynthesis, cannabinoid science, glaucoma and more.

Articles and videos

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent